WebNov 9, 2024 · Acrivon announced last Thursday that it would be offering 5.9 million shares at a range between $16.00 to $18.00. The IPO is due to price on Wednesday night, … WebAcrivon Pipeline. Acrivon’s Lead Program ACR-368 (also known as Prexasertib, in-licensed from Lilly), is a clinically-advanced, potent selective inhibitor of the DNA Damage Response checkpoint kinases, CHK1 and CHK2. ACR-368 has demonstrated deep, durable single-agent anti-tumor clinical activity, including complete responses, in a proportion ...
Acrivon Therapeutics Closes Oversubscribed $100 Million Series …
WebFrom standing start foundation → private company raises → IPO → commercialization → company sale. Built finance teams and setups with stage appropriate processes and compliance as an asset. WebOct 17, 2024 · Acrivon Therapeutics, Inc. S-1 IPO Report Mon Oct 17 2024 S-1 Registration of Securities October 2024 PDF Word S-1 Registration of Securities Acrivon Therapeutics, Inc. CIK: 1781174 GET DIRECTION ON YOUR INVESTMENTS Integrate SEC filing data within your own apps using our API Sign up Key Features hp 920 ink cartridge combo pack
Cancer Drug Company Acrivon Leads Biotech Ipos for Election …
WebJun 22, 2024 · WATERTOWN, Massachusetts, June 22, 2024 – Acrivon Therapeutics, Inc ., a clinical-stage oncology therapeutics company with proprietary proteomics-based technologies driving a new era of precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug … WebNov 15, 2024 · Acrivon previously raised roughly $120 million in private funding. Since its launch in 2024, it has secured Food and Drug Administration clearance to start a Phase … WebAcrivon Therapeutics Inc (NASDAQ:ACRV) Intrinsic Valuation. Check if ACRV is overvalued or undervalued under the bear, base, and bull scenarios of the company's future. hp 916xl black high-yield ink cartridge